-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
-
Summary
-
VYNE Therapeutics Inc. quarterly/annual Depreciation history and growth rate from Q1 2024 to Q2 2025.
- VYNE Therapeutics Inc. Depreciation for the quarter ending June 30, 2025 was $6K.
- VYNE Therapeutics Inc. annual Depreciation for 2024 was $4K.
- VYNE Therapeutics Inc. annual Depreciation for 2023 was $0.000, a 100% decline from 2022.